2026-12671NoticeWallet

Uncle Sam Investigates Germany for Not Paying Enough for New Drugs

Published Date: 6/24/2026

Notice

Summary

The U.S. is launching an investigation into Germany for not paying enough for new, innovative medicines. This could lead to changes in trade rules and possibly impact drug prices or tariffs. Public comments and a hearing will happen between June and September 2026, so everyone affected—especially pharmaceutical companies and patients—should pay attention!

Analyzed Economic Effects

4 provisions identified: 0 benefits, 3 costs, 1 mixed.

U.S. patients pay ~3.9× German prices

USTR states that U.S. consumers pay approximately 3.9 times as much as consumers in Germany for brand‑name drugs. USTR says this price gap results in the United States bearing a disproportionate share of global pharmaceutical R&D costs.

U.S. opens trade probe; tariffs possible

On June 18, 2026 the U.S. Trade Representative opened a Section 301 investigation into Germany for underpaying for innovative medicines. USTR is considering whether to take action, and the agency specifically asked commenters to consider tariff and non‑tariff actions as possible responses.

Germany ties confidentiality to 9% discount

USTR says Germany conditions confidentiality of manufacturers' pharmaceutical pricing on criteria that include acceptance of a 9 percent price discount and payment of additional administrative costs. USTR is examining this practice as one means by which Germany implements its pricing policies.

Draft German rebate could reach 20% by 2030

In 2026 Germany introduced draft legislation that would impose an additional mandatory rebate for patented medicines starting in 2027: a fixed 3.5 percent rate for the first half of 2027 and thereafter a variable rate tied to expenditures, with one estimate projecting the dynamic rebate could reach 20 percent by 2030. USTR cites this draft rebate as a policy reducing revenues for innovative medicines that it will examine in the investigation.

Your PRIA Score

Score Hidden

Personalized for You

How does this regulation affect your finances?

Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.

Free to start

Key Dates

Effective Date
Published Date
6/18/2026
6/24/2026

Department and Agencies

Department
Independent Agency
Agency
Trade Representative, Office of United States
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register